13 Acute HF Flashcards

1
Q

etiology/patho

  • includes with both HF ___ and HF ___
  • acute worsening of ___ HF accounts for 70% if cases (patients become refractory due to a realtively mild insult)
  • new acute HF is ~25% of cases
  • progressive worsening of ___ in chronic HF ~5% of cases
  • cardiogenic shock: hypotension (SBP < ___ mmHg or MAP < ___ mmHg) with low ___
A
  • HFrEF, HFpEF
  • chronic
  • CO
  • 90, 70, CO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Diagnostic Tools

non-invasive
detailed physical exam
- congestion
- adequacy of perfusion

lab assessment
- Cr, K, Na
- BNP and NTproBNP > ___ is closely associated with acute HF

A

400

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diagnostic Tools

invasive hemodynamic monitoring
- routine use is discouraged
- flow directed PA catheters ( ___ catheters)

A

Swan-Ganz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Maintaining Chronic Therapy While Hospitalized

GDMT should be continued in the absence of hemodynamic instability or CI (hypotension/cardiogenic shock)

Caution with aggressive diuresis and ___ / ___
- caution with increases and titrating up
- increases in SCr (~ ___ %) do not worsen outcomes

A

RAASi/SGLT2i
20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Maintaining Chronic Therapy While Hospitalized

Beta Blockers
- do not stop unless recent initiation or up-titiration resulted in current decompensation
- consider holding if ___ is needed or if hemodynamicaly ___
- do not add or up titrate until optimizational of volume status and successful D/C of IV diuretics, VDs and inotropes

A

dobutamine, unstable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Maintaining Chronic Therapy While Hospitalized

digoxin
- continue at a dose to achieve SDC ___ - ___ ng/mL
- avoid D/C unless compelling reason
- caution with regard to renal function

A

0.5-0.9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

management of decompensated episodes

  • diuretics, inotropes, vasodilators, vasopressors
  • no therapy shown to reduce mortality
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

drug therapy by classification

warm and dry

A

optimize chronic therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

drug therapy by classification

warm and wet

A

IV diuretics +/- venous vasodilator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

drug therapy by classification

cold and dry
- if PCWP < 15: IV ___ until PCWP 15-18
- if PCWP > 15 and SBP < 90: IV ___
- if PCWP > 15 and SBP > 90: IV ___ or arterial ___

A
  • fluids
  • iontrope
  • inotrope, arterial vasodilator
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

cold and wet
IV ___ and
if SBP < 90: IV ___
if SBP > 90: IV ___

A

diuretics
- inotrope
- arterial vasodilator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diuretics in hospitalized patients

  • used primarily to treat systemic/pulmonary ___ in subset ___ or ___
  • first line agents with fluid overload
  • initial IV dose should equal or ___ the chronic daily dose and be given as an intermittent bolus
  • loops more widely used; THZ used as add-on if refractory

if resistance
- ___ and ___ restriction
- increase ___ rather than ___ to ceiling
- add THZ
- ultrafiltration

A

congestion, II, IV
exceed
Na, water
dose, frequency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

diuretics in hospitalized patients

dosing
- increase dose patient was receiving at home
- if contiuous infusion: furosemide ___ mg/kg/hr doubled q2-4 hours; max ___

monitoring
- urine output and s/s of congestion
- ins/outs, body weight, vital signs, s/s perfusion and congestion
- desire ___ - ___ L/day above input ealy

A

0.1, 0.4
1-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

loop diuretics

furosemide ( ___ )
use
- fluid overload ( ___ )

PO/IV equivalent dose: ___ / ___

initial bolus and infusion rate
- ___ - ___ (10 mg/hr)

duration or response: ___ hours

AE
- Mg and K depletion
- hypotension
- worsened renal function

A

Lasix
- wet
- 80/40
- 40-120
- 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

loop diuetics

bumetanide ( ___ )
use
- fluid overload ( ___ )

PO/IV equivalent dose: ___ / ___

initial bolus and infusion rate
- ___ - ___ (0.5mg/hr)

duration or response: ___ hours

AE
- Mg and K depletion
- hypotension
- worsened renal function

A

Bumex
- wet
- 1/1
- 1-4
- 6

17
Q

loop diuretics

torsemide ( ___ )
use
- fluid overload ( ___ )

PO/IV equivalent dose: ___ / ___

initial bolus and infusion rate
- ___ - ___ (0.5 mg/hr)

duration or response: ___ hours

AE
- Mg and K depletion
- hypotension
- worsened renal function

A

Demadex
- wet
- 20/20
- 10-40
- 6

18
Q
A
19
Q

Vasodilator therapy

used in combo with diuretics to reduce pulmonary congestion in wet HF, stage ___ and ___
- venodilators increase venous capacities and reduce___ and myocardial ___
- rapid symptomatic relief
- ___ is venodilator of choice

patients with symptomatic ___ should not receive vasodilators
- should be considerd over ___
- frequent BP monitoring is needed

A

II, IV
preload, stress
NTG
hypotension
inotropes

20
Q

T or F: vasodilators have long t1/2

A

F; short

21
Q

Vasodilators

nitroprusside ( ___ )
clinical effects:
- balanced ___
- decreases SVR

use:
- warm and wet
- cold and wet (alt to inotropes)
- HTN ____

dosing
- ___ mcg/kg/min, titrate to response (max 3)

PK: t1/2 < ___ min

AEs:
- ___ and thiocyanate toxicity
- hypotension

A

Nitropress
- vasodilator
- cirsis
- 0.25
- 10
- cyanide

22
Q

vasodilators

NTG
clinical effects:
- ___ > arterial VD
- decreased PCWP

use:
- warm and wet
- ___ , HTN ___

dosing: ___ mcg/min initially, inc by 5 mcg/min every 5-10 min (max 200)

PK: t1/2 ~1-4 min

AE:
- hypotension
- HA
- reflex ___
- nitrate ____

A
  • venous
  • ACS, crisis
  • 5
  • tachycardia
  • tolerance
23
Q

vasodilators

nesiritide ( ___ )
clinical effects:
- balanced ___
- increase ____ output and ___ excretion

use:
- warm and wet
- cold and wet (alt to inotropes)

dosing:
- bolus ___ mcg/kg
- infusion: ___ mcg/kg/min, increase by ___ mcg/kg/min (max 0.03)

PK: t1/2 ~ 20 min

AE
- hypotension
- tachycardia
- renal dysfunction

A

Natrecor
- vasodilation
- urine, Na
- 2
- 0.01
- 0.005

24
Q

other vasodilators (3)

A

morphine, enalaprilat, hydralazine

25
Q

positive inotropes

beta-agonists (2)
PDE 3 inh (2)

A
  • dobutamine
  • dopamine
  • milrinone
  • amrinone

amrinone isnt used

26
Q

positive inotropes

dobutamine ( ___ )
MOA:
- B1 and B2 receptor ___ and weak a1 agonist
- stimulates AC to increase ___

clinical effects
- positive inotrope
- chronotrope
- lusitrope
- conside if low ___

use:
- cold and wet
- cold and dry (if PCWP > 15)

dosing
- ___ to ___ mcg/kg/min titrate

PK : t1/2 = 2 min

AE:
- arrhythmogenic
- tachycardia
- ischemia
- reduced K
- tolerance after 48-72 h

A

Dobutrex
- agonist
- cAMP
- BP
- 2.5, 5

27
Q

positive inotropes

milrinone ( ___ )
MOA:
- ___ inhibitor
- increase ___ in myocardium (increased ___ ) and vasculature (decreased ___ )
- “inodilator”

clinical effects:
- positive inotrope
- ___ > arterial VD
- consider if on ___

use
- cold and wet
- cold and dry (if PCWP > 15)

dosing:
- ___ - ___ mcg/kg/mi infusion titrate

PK: t1/2 ~ 1 hr (2-3 hrs in HF and CrCl < 50 )

AE
- arrhythmogenic
- tachycardia
- ischemia
- hypotension
- thrombocytpenia

A

Primacor
- PDE
- cAMP, CO, SVR
- venous
- BB
- 0.1-0.375

28
Q

positive inotropes

dopamine
MOA
- dose dependent ___ on D1R, B1, B2, and a1
- cause release of ___ from adrenergic nerve terminals

effects
- positive inotrope
- chronotrope
- lusitrope

use
- typically plays secondary role to ___ / ___
- sometimes referred to as a ___

dosing
- 0-3 mcg/kg/min - D1R, ___ vasculature VD, increased urine output
- 3-10 mcg/kg/min - B1, B2, increase myocardial ___ , SV, CO, and BP
- > 10 mcg/kg/min - a1, arterial ___ , increase SVR and BP,
- causes venous VC, increased PCWP, increases O2 demand (may worsen ___ )

PK: t1/2 = 2 min

AE
- arrhythmogenic
- tachycardia
- ischemia
- decreased ___
- tolerance after 48-72 hrs
- skin necrosis upon infiltration

A
  • agonist
  • NE
  • dobutamine/milrinone
  • vasopressor
  • renal
  • contractility
  • vasoconstriction
  • ischemia
  • K
29
Q

positive inotropes ___ curve

A

raise

30
Q

ADHR: positive inotrope therapy

  • primarily to manage ___ or cold HF patients
  • reasonable to consider ___ before inotropes when adequate BP
  • useful for symptom relief in hypotension (SBP < ___ )
  • useful in patients with end ___ dysfunction (AKI, altered mental status, systemic hypoperfusioin, hypotension, CV collapse)
  • useful when disease is ___ to other HF therapies (need for mechanical circulatory support/transplant/palliative care)
  • choice of dobutamine vs milrinone is individualized (low ___ vs ___ use)
A
  • hypoperfusion
  • vasodilators
  • 90
  • organ
  • refractory
  • BP, BB
31
Q

management of decompensation episodes overview

Diuretic therapy
- IV ___ diuretics for patients with fluid overload
- change to PO route on day before discharge if possible
- when response to duretics is minimal, consider other options

A

loop

32
Q

management of decompensation episodes overview

inotropic therapy

relieve symptoms and improve end-organ function in patients with reduced LVEF and diminished perfusion or end-organ dusfunction, esp if:
- SBP < ___
- symptomatic ___ despite adequate filling pressure
- no response to/intolerance of IV ___

patients with evidence of fluid overload and ___ to IV diuretics or they are associated with worsening ___ functions

A
  • 90
  • hypotension
  • vasodilators
  • unresponsive, renal
33
Q

management of decompensation episodes overview

vasodilator therapy
- may be considered in addition to IV ___ to rapidly improve symptoms in patients with acute PE or severe HTN
- may be considered in patients with persistent symptoms despite aggressive diuretics and PO drug therapy
- when adjunctive therapy is necessary in addition to loop diuretics, IV vasodilators should be considered over ___ drugs

A
  • loop diuretics
  • inotropic